Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neharika Jain

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Valued at a market cap of $82.9 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, manufactures, and commercializes medicines for treating various serious medical diseases. The Tarrytown, New York-based company’s portfolio boasts nine marketed drugs, which are Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV. 

Companies valued at $10 billion or more are generally described as “large-cap” stocks, and Regeneron Pharmaceuticals fits right into that category. The biotech company is considered a pioneer in antibody research and is known for developing innovative medicines for patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and various other rare diseases. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.